美国食品和药物管理局批准使用Cologuard Plus和Shield进行结直肠癌查. FDA approves Cologuard Plus and Shield blood tests for colorectal cancer screening.
美国食品和药物管理局批准了两种新的结直肠癌查测试:Cologuard Plus和盾牌血液测试. The FDA has approved two new colorectal cancer screening tests: Cologuard Plus and the Shield blood test. Cologuard Plus 是一种粪便 DNA 测试，显示 95% 的癌症敏感性，旨在鼓励 45 岁及以上处于平均风险的成年人进行筛查。 Cologuard Plus, a stool DNA test, shows 95% cancer sensitivity and aims to encourage screenings among adults 45 and older at average risk. Shield 测试是一项血液测试，可检测到 83% 的结直肠癌，但仅可检测到 13% 的危险息肉。 The Shield test, a blood test, detects 83% of colorectal cancers but only 13% of dangerous polyps. 这两种检测都为传统结肠镜检查提供了较少侵入性的替代品,有可能增加筛查率。 Both tests offer less invasive alternatives to traditional colonoscopy, potentially increasing screening rates.